FDA Classifies BMC Luna G3 APAP Ventilator Recall as Class I in 2026: Firmware Defect and Up to 196 Devices Not Updated

Recall and Safety Notice

Published: October 1, 2026, 19:31

Event Overview

On August 19, 2026, the U.S. Food and Drug Administration (FDA), in its Medical Device Recall Database, classified the recall of the Luna G3 APAP ventilator, model LG3600, by BMC Medical Co., Ltd. (Beijing), as a Class I recall. The recall number is Z-2979-2026 and the event number is 99445. A Class I recall is the most serious category of FDA device recall, meaning that continued use may cause serious health harm or death. FDA posted the company announcement on September 8, 2026; the company announcement date stated in the notice is September 7, 2026. This article reviews the timeline, affected products and identification information, failure mode, and key points that companies should consider in correction and reporting processes.

Timeline: A Retrospective Report

According to FDA and the company announcement, this recall was a retrospective report. BMC reported the recall to FDA only on July 15, 2026, and the announcement also states that the corrective action was not reported to customers at that time. The device issue occurred earlier: affected devices were manufactured from September 11 to October 18, 2024; BMC shipped them to the U.S. importer React Health from September 20 to October 19, 2024; and they were distributed nationwide in the United States between October 29, 2024 and July 6, 2026.

Technical Cause and Failure Mode

The announcement states that firmware version G3-2.00.76 installed on these devices contains a defect. From October to December 2024, BMC upgraded 20,160 affected devices to G3-2.00.77 at the U.S. importer warehouse. However, after the retrospective recall report, BMC found that up to 196 devices may not have been upgraded and remained at firmware version G3-2.00.76. The failure condition occurs when three parameters are simultaneously high: high pressure, high respiratory rate, and high peak flow. At that point, the device display triggers an Error prompt and the device then automatically shuts down, preventing continued therapy delivery.

Affected Product and Identification Information

The affected product is the Luna G3 APAP, model LG3600, with UDI 06948538363331 and 06948538365892. The product classification is a continuous positive airway pressure device (product code MNS). The FDA database lists the recall status as Open, Classified. The company announcement states that, as of the date of the announcement, no complaints or serious adverse event reports related to this firmware failure had been received. The serial number list and firmware version query portal are provided by the company on its official website.

Impact and Requirements for Users

The announcement requires affected devices still operating on firmware version G3-2.00.76 to be stopped immediately until replacement devices are obtained. Users can read the serial number on the label on the back of the device, verify the firmware version on the company query page, or contact the U.S. importer React Health for a replacement device. For manufacturers and exporters, the key issue in this case is not technical difficulty but process: completing a technical fix first, reporting the recall only afterward, and failing to notify customers at the same time ultimately led FDA to classify the action as a Class I recall and make it public. This path amplifies both regulatory risk and market trust costs.

Sources and Applicability

Source: U.S. Food and Drug Administration (FDA) company announcement, BMC Medical Co., Ltd. Recalls Luna G3 APAP (Model LG3600) with Firmware G3-2.00.76 Due to Firmware Defect, FDA posting date September 8, 2026 (company announcement date September 7, 2026): https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bmc-medical-co-ltd-recalls-luna-g3-apap-model-lg3600-firmware-g3-20076-due-firmware-defect

FDA Medical Device Recall Database record (recall number Z-2979-2026, publication date August 19, 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221571

Verification scope and access date: this verification covered the above two types of pages, the FDA official company announcement page and the FDA device recall database record page, with an access date of October 1, 2026. Applicability note: this article is an interpretation of publicly available U.S. FDA regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. Recall information is subject to the official original text and may change with subsequent official updates.

Source Information

• U.S. Food and Drug Administration (FDA) - Recalls, Market Withdrawals, & Safety Alerts, 2026-09-08
• U.S. Food and Drug Administration (FDA) - Medical Device Recall Database, 2026-08-19

AIMEILI Regulatory Interpretation

This case shows that FDA assesses not only whether a technical correction reduces risk, but also whether the manufacturer timely reported and communicated the field action. A firmware upgrade performed at an importer warehouse can substantially reduce risk, but it does not eliminate the obligation to report a correction intended to reduce a risk to health. Under FDA correction and removal reporting requirements, a manufacturer generally must submit a report within 10 working days after becoming aware of information reasonably suggesting that a reportable correction or removal has been initiated. Failure to notify customers can make the field action appear incomplete and can contribute to a more severe recall classification. A Class I classification means there is a reasonable probability that use of the device will cause serious adverse health consequences or death. Retrospective reporting can increase FDA scrutiny, enforcement exposure, and reputational harm. The finding that up to 196 devices remained at defective firmware despite a 20,160-device upgrade also highlights the need for closed-loop effectiveness checks, reconciliation, and serial-number-level traceability.

Business Impact

For manufacturers, importers, distributors, CROs, and regulatory affairs teams, this recall has immediate operational, compliance, and commercial implications. Operationally, affected inventory must be quarantined, serial numbers and firmware versions must be verified, replacement devices must be shipped, and customer-facing communication must be prepared. Commercially, a public Class I recall can affect hospital procurement, tender evaluations, distributor confidence, and insurer or payer scrutiny. From a compliance perspective, companies should review correction and removal procedures, health hazard evaluation records, customer notification templates, effectiveness check plans, UDI and serial number traceability, and coordination with U.S. agents and importers. The case also demonstrates that a technically successful upgrade is not enough if reporting and customer communication are delayed; timely regulatory notification and documented field-action closure are essential to limit enforcement risk and preserve market trust.